KB 5XX
Alternative Names: KB5-XXLatest Information Update: 27 Nov 2023
At a glance
- Originator Krystal Biotech
- Class Gene therapies; Skin disorder therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 27 Nov 2023 Discontinued - Preclinical for Skin disorders in USA (Parenteral) (Krystal Biotech pipeline, November 2023)
- 02 Feb 2023 Preclinical trials in Skin disorders in USA (Parenteral) (Kyrstal Biotech pipeline, January 2023)
- 01 Jun 2021 Early research in Skin disorders in USA (Parenteral) before June 2021